BUPROPION-SR FOR SMOKING CESSATION IN EARLY RECOVERY FROM ALCOHOL DEPENDENCE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是确定如何有效的药物，安非他酮-SR，是治疗酒精依赖早期恢复戒烟。 安非他酮-SR是一种已被美国食品和药物管理局（FDA）批准用于治疗戒烟的药物。 我们希望这种药物将有助于在酒精依赖早期恢复的患者中开始戒烟并保持戒烟。 绝大多数接受酒精依赖治疗的患者也吸烟。 吸烟与严重的预防性健康风险和过早死亡有关。 研究表明，那些接受酒精依赖治疗和戒烟的人也不太可能复发酒精使用。 18岁或以上的男性和女性，符合酒精和尼古丁依赖的研究标准，并且已经戒酒6周至6个月，可能有资格参加。 他们必须表明戒烟的愿望，并确定一个“戒烟日期”。“此外，个人必须能够确定我们可以联系的家庭成员或朋友，以询问他们的酒精和烟草使用情况。 如果有任何癫痫发作、严重头部创伤、脑肿瘤或中风病史，则不能参加研究。 同样，如果他们服用任何可能使其不适合服用安非他酮SR的药物，他们也不能参加。患有医学或精神疾病的人，或目前依赖或大量使用其他药物的人不符合资格。 哺乳期、妊娠期或可能在本研究期间妊娠的女性也不合格。 本研究将从Chelsea Arbor治疗中心共招募80例受试者。 我们将按照完成初步评估的顺序录取有资格参加这项研究的人。 通过参加本研究，您可能会戒烟，因此，您的整体健康状况可能会改善。 最重要的是，你可能会提高你持续清醒的机会。 您将接受治疗师、精神科医生、执业护士和/或注册护士的定期访视，以帮助您戒酒和戒烟。 大约一半的研究参与者将免费服用安非他酮SR。 研究表明，如果你参加戒烟咨询，你成功戒烟的机会比你自己戒烟的机会更大。 那些除了接受戒烟咨询外还接受积极药物治疗的人可能会在戒烟方面取得更大的成功。 '

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine how effective the medication, bupropion-SR, is for treating smoking cessation during early recovery from alcohol dependence. Bupropion-SR is a medication that has been approved by the United States Food and Drug Administration (FDA) for the treatment of smoking cessation. We expect that this medication will be useful in initiating smoking cessation, and maintaining abstinence from smoking, among patients in early recovery from alcohol dependence. A vast majority of patients treated for alcohol dependence also smoke cigarettes. Cigarette smoking is associated with serious, preventative health risks, and premature death. Studies have shown that those who are treated for alcohol dependence, and who quit smoking, are also less likely to relapse to alcohol use. Men and women, 18 years of age or older, who meet study criteria for alcohol and nicotine dependence, and who have been abstinent from alcohol for 6 weeks to 6 months, may be eligible to participate. They must state a desire to quit smoking and identify a "quit date." In addition, individuals must be able to identify a family member or friend whom we can contact to ask about their alcohol and tobacco use. Individuals cannot participate if they have any history of seizure disorder, severe head trauma, brain tumor, or stroke. Likewise, they cannot participate if they take any medications that may make it inadvisable to take bupropion-SR. Individuals who have a medical or psychiatric illness, or who are currently dependent on, or heavily use other drugs are ineligible. Women who are nursing, pregnant, or likely to become pregnant during this study are also ineligible. A total of 80 subjects will be recruited for this study from Chelsea Arbor Treatment Center. We will admit people who qualify for this study in the order that they complete the initial assessments. By joining this study, you may quit smoking, and, therefore, your overall health may improve. Most importantly, you could possibly improve your chances of sustained sobriety. You will receive regular visits with a therapist, psychiatrist, nurse practitioner, and/or registered nurse to help you with your abstinence from alcohol and cigarettes. Approximately one-half of study participants will be given bupropion-SR, at no cost. Research indicates that you have a greater chance of successfully quitting smoking if you participate in smoking cessation counseling than if you try to quit on your own. Those who are receiving active medication in addition to smoking cessation counseling may have even greater success in quitting. '